TAKEDA PHARMACEUTICAL CO LTD

TAK · XNYS

CIK 1395064fmd_0PMH94341VM7KDDJNYKRM02K9BManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Apr 02, 2015 to Mar 31, 2025, 31 periods

Income Statement · Annual · Millions · JPY
Line item	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	1,732,051	1,770,531	2,097,224	3,291,188	3,197,812	3,569,006	4,027,478	4,263,762	4,581,551
Cost of revenue	558,755	495,921	651,729	1,089,764	994,308	1,106,846	1,244,072	1,426,678	1,580,217
Gross profit	1,173,296	1,274,610	1,445,495	2,201,424	2,203,504	2,462,160	2,783,406	2,837,084	3,001,334
Research and development	312,303	325,441	368,298	492,381	455,833	526,087	633,325	729,924	730,227
Operating income	155,867	241,789	237,685	100,408	509,269	460,844	490,505	214,075	342,586
Interest expense	23,249	31,928	83,289	165,006	248,631	166,607	169,698	219,850	210,065
Income before taxes	143,346	217,205	127,612	(60,754)	366,235	302,571	375,090	52,791	175,084
Income tax expense	27,833	30,497	(7,468)	(105,044)	(9,936)	72,405	58,052	(91,406)	66,941
Net income from continuing operations	115,513	186,708	135,080	44,290	376,171	230,166	317,038	144,197	108,143
Net income	114,940	186,886	135,192	44,241	376,005	230,059	317,017	144,067	107,928
Net income to common shareholders	114,940	186,886	135,192	44,241	376,005	230,059	317,017	144,067	107,928